Leukemias in the Context of Rheumatoid Arthritis: Shared Pathways and Clinical Perspectives

Area of Science:

• Rheumatology
• Hematology
• Oncology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease causing systemic inflammation and joint damage.
• RA patients exhibit an increased incidence of hematological cancers, particularly leukemias.
• Shared pathogenic mechanisms, including chronic inflammation and immune dysregulation, link RA and leukemia.

Purpose of the Study:

• To explore the association between rheumatoid arthritis and leukemia.
• To elucidate the shared mechanisms driving this comorbidity.
• To discuss clinical implications and future research directions.

Main Methods:

• Review of existing literature on RA, inflammation, and leukemia.
• Analysis of pathogenic pathways involving cytokines (TNF-α, IL-6) and genetic mutations (STAT3, TET2, DNMT3A).
• Evaluation of the impact of RA treatments (MTX, JAK inhibitors, anti-TNF) on leukemia risk.

Main Results:

• Chronic inflammation and immune dysregulation in RA create a microenvironment conducive to leukemic transformation.
• Specific genetic alterations are implicated in both RA pathophysiology and hematologic malignancies.
• Certain RA treatments may influence leukemia risk through immune suppression and hematopoietic changes.

Conclusions:

• The association between RA and leukemia necessitates enhanced surveillance and risk stratification for RA patients.
• Interdisciplinary collaboration between rheumatologists and hematologists is crucial for managing treatment risks.
• Future research should focus on biomarkers, targeted therapies, and AI-driven risk modeling for personalized care.